Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of
cisplatin and it remains just as useful now as it did back then, especially for the treatment of …

Despite the development of second-generation antiandrogens, acquired resistance to
hormone therapy remains a major challenge in treating advanced prostate cancer. We find …

All aspects of prostate cancer evolution are closely related to androgen levels and the status
of the androgen receptor (AR). Almost all treatments target androgen metabolism pathways …

Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription
factor. In most cases, AR activity resumes during therapy and drives progression to …

MiR-374a appears to play a complex role in non-small-cell lung cancer (NSCLC). Here, we
demonstrate a dual role for miR-374a in NSCLC pathogenesis. The effects and modulatory …

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen
deprivation therapy (ADT). Second-generation antiandrogens have a role in castration …

Primary prostate cancer can have extensive microheterogeneity, but its contribution to the
later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains …

Sigma1 (also known as sigma-1 receptor, Sig1R, σ1 receptor) is a unique pharmacologically
regulated integral membrane chaperone or scaffolding protein. The majority of publications …

Disseminated castration‐resistant prostate cancer (CRPC) is a common disease in men that
is characterized by limited survival and resistance to androgen‐deprivation therapy. The …